Clinical trials have validated that ER‐positive patients of otherwise high clinical risk, but classified as low risk by the 70‐gene signature, may not benefit from adjuvant chemotherapy,14 and this molecular risk prediction tool is implemented in several breast cancer treatment guidelines.15, 16, 17. Here, ESR1 is linked to breast carcinoma.